GMT: Net loss deepened to PLN 6.6M as R&D spending rose; commercialization still ahead
· Issued by Genomtec Sa
R&D-focused biotech reported a net loss of PLN 6.6M for H1 2025, with minimal sales and increased R&D spending. Key milestones include new patents, a PLN 10.8M capital raise, and progress in flagship diagnostic projects, but commercialization remains pending.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
